Oncology and Carcinogenesis articles for National Institutes of Health (NIH), United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 160

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
1 1.00
Multiplexed Nanoscale Viscoelastic Mapping at Multiple Time Scales of Melanoma Cells as a Label-Free Cancer Biomarker 1.00
2 1.23
Metabolomic profiling of genotype-derived ABO blood group, secretor status and Lewis antigens and association with pancreatic ductal adenocarcinoma risk 0.90
Body size and occupational physical activity during the life course and gastrointestinal cancers 0.33
2 0.24
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes 0.10
Genetic analysis in African ancestry populations reveals genetic contributors to lung cancer susceptibility 0.14
1 0.27
YAP AND TEAD ARE TRANSCRIPTIONAL REGULATORS OF NEUROENDOCRINE DIFFERENTIATION AND GROWTH IN CARCINOID CELLS 0.27
3 0.41
Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations. 0.05
Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups. 0.06
Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population. 0.31
1 0.00
Implementation of Comprehensive Surgical Guidelines for Hepatoblastoma: Analysis of the Children's Oncology Group AHEP0731 Phase III Trial. 0.00
2 0.18
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT 0.03
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.15
1 0.05
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer 0.05
3 1.15
Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma 0.26
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer 0.23
Spatial Profiling Identifies Regionally Distinct Microenvironments and Targetable Immunosuppressive Mechanisms in Pediatric Osteosarcoma Pulmonary Metastases 0.66
1 0.10
Inhibition of oligomeric BAX by an anti-apoptotic dimer 0.10
2 0.39
New and Growing Nodules Are Associated Strongly With Malignancy in Follow-Up Screening for Lung Cancer 0.17
Comparison of Underlying Risk of Developing and Dying from Lung Cancer in Screened Populations 0.22
1 0.53
Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001–2019 0.53
2 1.75
Cohesin-mediated stabilization of the CCAN complex at kinetochores in mitosis 0.75
Spindle checkpoint can secure additional cheating time for selfish expanded centromeres 1.00
1 0.04
Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study 0.04
2 0.77
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates iZFP36L2/i as a driver gene for pancreatic ductal adenocarcinoma 0.75
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.02
1 0.07
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.07
1 0.21
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment 0.21
2 0.87
Using Mendelian randomization to investigate etiologic heterogeneity across renal cell carcinoma subtypes 0.75
Body mass index and gastric cancer risk: results from the Stomach Cancer Pooling Project Consortium 0.12
1 0.06
Biomarker-Based Eligibility for Lung Cancer Screening: Validation of the Protein-Based INTEGRAL-Risk Model. 0.06
3 0.94
KRAS4a and KRAS4b show distinct lipid-dependent regulation of RAS-RAF membrane dynamics 0.15
Auxin-Induced Depletion of Human CCR4-NOT Subunits Reveals Opposing Functions of CNOT1 and CNOT4 in mRNA Metabolism 0.14
5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells 0.64
1 0.06
Plasticity of mitotic cyclins in promoting the G2–M transition 0.06
9 3.74
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers 0.04
Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma 0.06
Interlocking host and viral cis-regulatory networks drive Merkel cell carcinoma 0.71
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion 0.14
The functionally conserved human lncRNA motif GULF lowers glucose and lipid levels in obese mice 1.00
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy 0.07
CBFβ-SMMHC–driven leukemogenesis requires enhanced RUNX1-DNA binding affinity in mice 0.95
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING 0.74
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer 0.02
6 1.21
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). 0.05
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. 0.02
Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533. 0.01
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. 0.05
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. 0.09
Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma. 1.00
2 1.13
Safety, immunovirological, and CNS effects of PD-1 inhibition in people with HIV without malignancy 0.86
Profiling Human Papillomavirus Lineage-Specific Capsid Antigenicity With Geographically Diverse Natural Infection Antibodies 0.27
1 0.63
Population differences in Merkel cell carcinoma by virus status and anatomic site: A multi-cohort analysis including institutional, SEER, and NCDB data 0.63
18 5.09
Belzutifan Efficacy in Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma Versus Natural History Control Arm 0.33
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid Tumors 0.08
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes 0.06
Methylation signatures distinguish non small cell lung cancer subtypes and associated with survival in smokers with lung squamous cell carcinoma 0.13
Identifying expression and DNA methylation biomarkers for lung adenocarcinoma risk in East Asia 0.23
Postpartum breast cancer: evidence for a distinct phenotype 0.08
Sex steroid hormones, gonadotropins, and risk of testicular germ cell tumors: results from the STEED study 0.44
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.29
Personalizing lung cancer screening recommendations for heterogenous populations: a microsimulation study 0.14
Time-dependent relationship between urinary biomarkers of nucleic acid oxidation and colorectal cancer risk 0.17
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.14
Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers 0.79
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study 0.09
Gaps in care across the cancer screening continuum for cervical, colorectal, and lung cancers 0.07
Germline rare variants in cancer susceptibility genes and subsequent neoplasm risk after childhood cancer 1.00
Incidence of rare cancers during the COVID-19 pandemic: a US population-based study 0.80
Trends in uterine cancer incidence and mortality: insights from a natural history model 0.18
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults 0.08
2 1.71
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAs 0.78
RNA-coupled CRISPR screens reveal ZNF207 as a regulator of LMNA aberrant splicing in progeria 0.93
5 1.11
Tumour–brain crosstalk restrains cancer immunity via a sensory–sympathetic axis 0.18
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.33
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity 0.31
Neutrophils drive vascular occlusion, tumour necrosis and metastasis 0.02
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.26
1 0.78
Nonsense-mediated mRNA decay safeguards telomeres in pluripotent stem cells 0.78
29 10.40
Functional implications of the conformational landscape of a multidrug transporter revealed by Zebrafish Abcb4 structures 1.00
Fusion-positive rhabdomyosarcoma oncofusions share a common interactome 0.06
Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations 0.13
MYC-induced USP10 stabilizes SOX4 to promote thymocyte proliferation and leukemia onset in mice 0.08
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.01
Structural basis for prostaglandin and drug transport via SLCO2A1 0.14
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study 0.92
A large-scale genome-wide association meta-analysis for nevus count provides direct insights into the genetics of melanoma 0.03
A spatially resolved human glioblastoma atlas reveals distinct cellular and molecular patterns of anatomical niches 0.04
Inhibition of stress resilience and adult hippocampal neurogenesis by platelet-derived LPA16:0 in anxiety 0.10
Control of telomerase recruitment and end protection by independent shelterin components 1.00
Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors 0.40
The molecular cartography of malignant and benign sebaceous tumours 0.08
Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 0.07
Enhancer regulator MLL4 controls skeletal muscle metabolic efficiency by limiting AMPK-mediated fuel catabolism 0.04
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling 0.85
Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci 0.00
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer 0.17
An active allosteric mechanism in ASAP1-mediated Arf1 GTP hydrolysis redefines PH domain function 0.77
Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma 0.56
Multivalent interactions with CCR4–NOT and PABPC1 determine mRNA repression efficiency by tristetraprolin 0.93
Allosteric activation of the SPRTN protease by ubiquitin maintains genome stability 0.11
Comprehensive ovarian cancer variant analysis uncouples homologous recombination and replicative functions 0.05
Marked heterogeneity in malaria infection rate in a Malian longitudinal cohort 0.10
Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma 0.75
Molecular patterns and mechanisms of tumorigenesis in HPV-associated and HPV-independent sinonasal squamous cell carcinoma 0.21
Control of epithelial tissue organization by mRNA localization 0.90
The TRIP12 E3 ligase induces SWI/SNF component BRG1-β-catenin interaction to promote Wnt signaling 0.03
Inflammatory diseases and risk of lung cancer among individuals who have never smoked 0.87
4 0.22
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.02
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.01
Childhood brain tumors instruct cranial hematopoiesis and immunotolerance 0.06
Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry 0.14
1 0.18
PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming 0.18
1 0.05
Restoring the tumour mechanophenotype of vocal fold cancer reverts its malignant properties 0.05
5 0.53
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial 0.10
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial 0.04
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial 0.28
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial 0.09
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial 0.03
1 0.06
TDP-43 loss induces cryptic polyadenylation in ALS/FTD 0.06
2 0.99
DICER1 hotspot mutation induces 3p microRNA gain of function via Argonaute strand switch 0.94
Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification 0.05
1 0.74
ATF2 phosphorylation is a core transcriptional driver of neuron apoptosis 0.74
1 0.04
TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementia 0.04
3 2.06
Lactate and histone H3K18 lactylation are associated with metabolic control of gene expression in the retina 0.81
Clusters of deep intronic RbFox motifs embedded in large assembly of splicing regulators sequences regulate alternative splicing 0.75
Cell cycle dependent methylation of Dam1 contributes to kinetochore integrity and faithful chromosome segregation. 0.50
8 2.02
The antimetastatic effects of calorie restriction are negated by voluntary exercise in an aggressive breast cancer mouse model 0.82
The lysosomal carrier SLC29A3 supports antibacterial signaling, and promotes autophagy by activating TRPML1 in murine dendritic cells 0.33
Biliverdin reductase A is a major determinant of protective NRF2 signaling 0.09
An in vitro BRAF activation assay elucidates molecular mechanisms driving disassembly of the autoinhibited BRAF state 0.44
G-quadruplexes as a source of vulnerability in BRCA2-deficient granule cell progenitors and medulloblastoma 0.07
Akt isoform specificity drives intrinsic immune regulation during HSV-1 infection 0.13
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity 0.07
Epithelial Regnase-1 inhibits colorectal tumor growth by regulating IL-17 signaling via degradation of NFKBIZ mRNA 0.07
3 0.55
Structural basis for LZTR1 recognition of RAS GTPases for degradation 0.33
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction 0.19
In vivo CAR T cell generation to treat cancer and autoimmune disease 0.03
11 4.35
SRSF3 determines Treg cell fate in antitumor immunity and autoimmunity 0.33
Generalizability of an AI-based mammogram risk score (MRS) for breast cancer among diverse populations of women 0.25
Accessory microRNA byproducts expand RNA interference via microprocessor-mediated cleavage activation 0.07
Pyruvate kinase muscle 2 (PKM2) promotes CD4 T cell survival by regulating pyruvate oxidation during homeostasis and expansion 0.78
Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation 0.17
Substrate recognition by human separase 0.20
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup 0.03
Id1 promotes clonal hematopoiesis in mice with Tet2 loss of function 0.90
Distinctive molecular features of radiation-induced thyroid cancers 0.58
Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML 0.50
Chemokines kill bacteria without triggering antimicrobial resistance by binding anionic phospholipids 0.54
2 0.13
Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases 0.03
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells 0.10
1 0.23
Well-differentiated systemic mastocytosis: genetics, mast cell immunophenotypes, and KIT autophosphorylation 0.23
1 0.24
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.24
6 1.05
Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study 0.59
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.02
Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial 0.14
Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study 0.07
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study 0.05
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group 0.17
2 1.84
Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling 0.92
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer 0.93

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.